Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery
Proceedings of the National Academy of Sciences · 14.04.2026 · 123 (15)
DOI: 10.1073/pnas.2600197123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.04.2026. Verfasst von Sarah D Davey und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Aberystwyth University, Wales, Aberystwyth SY23 3DA, United Kingdom. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Schistosoma mansoni, Drug Discovery, Schistosomiasis mansoni. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome, UK Research and Innovation (UKRI).
Abstract (Originalsprache)
Control of schistosomiasis, a neglected tropical disease caused by infection with Schistosoma spp ., remains reliant on a single chemotherapy, praziquantel (PZQ). This strategy presents a risk to global health should PZQ-resistant schistosomes establish in endemic areas and justifies the search for new drugs. However, species-specific metabolic differences between humans and preclinical models hinder the optimization of next-generation anti-schistosomal therapeutics. Here, to bypass these species-specific limitations, we exploited a humanized mouse model, 8HUM, engineered to express the principal human Phase I cytochrome P450 enzymes (CYP1A1/2, CYP2C9, CYP2D6, CYP3A4/7) as well as the transcription factors constitutive androstane receptor and pregnane X receptor in place of 35 murine orthologs. We characterized Schistosoma mansoni development, immunopathology, hepatic transcriptomic responses, intestinal microbiome changes, and PZQ metabolism as well as PZQ efficacy in 8HUM vs. wild-type (WT) mice. 8HUM mice supported normal S. mansoni maturation, infection-associated microbiome dysbiosis, Th2-dominant immune responses, and characteristic hepatic pathology. PZQ intrinsic clearance in 8HUM hepatic microsomes mirrored human levels and was >10-fold lower than that found for WT microsomes. Oral dosing revealed human-like PZQ exposures of ( R )-PZQ and 4OH-PZQ in 8HUM mice at 25 mg/kg bodyweight and >90% reductions in worm burdens at 100 mg/kg bodyweight (equivalent to that seen in WT mice administered PZQ at 400 mg/kg bodyweight). Our results revealed that 8HUM mice recapitulate key features of murine schistosomiasis while exhibiting human-relevant drug metabolism. These findings establish 8HUM as a refined translational platform for anti-schistosomal drug development, improving predictive accuracy and accelerating therapeutic discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Aberystwyth University, Wales, Aberystwyth SY23 3DA, United Kingdom.
- Lydia Becker Institute of Immunology and Inflammation, Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, England, Manchester M13 9NT, Un…
- Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, Scotland DD1 5EH, United Kingdom.
- Department of Computer Science, Aberystwyth University, Wales, Aberystwyth SY23 3DA, United Kingdom.
- Laboratory of Inflammation and Infectious Diseases, Department of Morphology and Pathology, Federal University of São Carlos, São Carlos CEP 13565-905, Brazil.
ORCID-Profile: Sarah D Davey, Josephine E Forde-Thomas, Benjamin J Hulme, Kristin Lees, Gabriel Rinaldi, Frederick R C Simeons, Remi Pichon, Yi-Hsuan Lee, Iain W Chalmers, Bismark Dankwa, Brenda Kisia Odhiambo, Victor Hugo Guimaraes, Andrew S MacDonald, Ian H Gilbert, Beatriz Baragaña, Kevin D Read, Karl F Hoffmann
Förderung
- Wellcome
- UK Research and Innovation (UKRI)
Zitieren
APA
Davey, S. D., Forde-Thomas, J. E., Hulme, B. J., Lees, K., Costain, A. H., Evans, M., Rinaldi, G., Frame, L., Stojanovski, L., Simeons, F. R. C., Tavendale, A., MacLeod, A. K., Pichon, R., Lee, Y. H., Polak, O., Chalmers, I. W., Dankwa, B., Odhiambo, B. K., Guimaraes, V. H., …, & Hoffmann, K. F. (2026). Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery. Proceedings of the National Academy of Sciences, 123(15). https://doi.org/10.1073/pnas.2600197123
Vancouver
Davey SD, Forde-Thomas JE, Hulme BJ, Lees K, Costain AH, Evans M, et al. Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery. Proceedings of the National Academy of Sciences. 2026;123(15). doi:10.1073/pnas.2600197123
BibTeX
@article{Davey2026,
author = {Davey, Sarah D and Forde-Thomas, Josephine E and Hulme, Benjamin J and Lees, Kristin and Costain, Alice H and Evans, Mary and Rinaldi, Gabriel and Frame, Laura and Stojanovski, Laste and Simeons, Frederick R C and Tavendale, Amy and MacLeod, A Kenneth and Pichon, Remi and Lee, Yi-Hsuan and Polak, Oktawia and Chalmers, Iain W and Dankwa, Bismark and Odhiambo, Brenda Kisia and Guimaraes, Victor Hugo and Hegarty, Matthew and Swain, Martin T and Aubrey, Wayne and Caldwell, Nicola and MacDonald, Andrew S and Gilbert, Ian H and Baragaña, Beatriz and Read, Kevin D and Hoffmann, Karl F},
title = {Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {15},
doi = {10.1073/pnas.2600197123}
}
EUVIMED